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The PTPRG gene is composed of 30 exons and is 
approximately 780 kb in size. 
Transcription 
The transcript length is 4338 bp. An alternatively 
spliced variant has been reported with a transcript 
length of 5655 bp. 
Pseudogene 
No pseudogenes have been reported. 
Protein 
Description 
Amino acids: 1445. Molecular weight: 162058 Daltons. 
The PTPRG gene belongs to the receptor class 5 
subfamily of the protein-tyrosine phosphatase family. 
Expression 
PTPRG is expressed in several tissues. 
Localisation 
Membrane. Single-pass type I membrane protein. 
Function 
Involved in regulating signaling through ligand-
controlled protein tyrosine dephosphorylation. The 
protein contains an extracellular carbonic anhydrase-
like and fibronectin type III-like domain, a single 
transmembrane domain, and a cytoplasmic region with 
2 tandem catalytic tyrosine phosphatase domains. Y2H, 
animal models. 
Homology 
PTPRG shares a PTP domain, involved in 
dephosphorylating phosphorylated tyrosine residues, 
with the other receptor-like protein tyrosine 
phosphatases. The PTPRG gene is conserved in 
vertebrates. The human and mouse (1442-amino acid) 
sequences share 95% identity at the amino acid level. 
Mutations 
Germinal 
No germline mutations have been reported. 
Somatic 
8 different missense mutations in the PTPRG gene have 
been identified in colon carcinomas: C1082T (T361M), 
C1385T (A462V), C1541T (T514M), C1777T 
(R593W), A2864G (E955G), A2918G (Y973C), 
C3934T (R1312W) A3976G (I1326V). 
Loss of heterozygosity (LOH) of a region which 
includes the PTPRG locus has been shown in clear 
renal cell carcinoma, lung carcinoma and colon 
carcinoma. 
Implicated in 
Note: PTPRG has been considered a potential tumor 
suppressor gene based on its function, antagonizing 
activity of protein tyrosine kinases that often function 
as oncoproteins. Secondly, because it maps to a region 
of human chromosome 3, 3p21, that is frequently 
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deleted in renal cell carcinoma and Lung carcinoma. 
Thirdly, because PTPRG has been shown to harbor 
point mutations in a subset of colon carcinomas. 
Fourthly, because the PTPRG gene shows promoter 
hypermethylation in cutaneous T-cell lymphoma and 
melanoma. Finally, lower expression levels of PTPRG 
have been reported for a number of cancerous tissues 
including gastric cancer. 
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